Abiopharma

BioRegenx, Inc. is advancing the future of health intelligence through patented technologies and artificial intelligence. Focused on the development and acquisition of high-value intellectual property, we operate at the intersection of regenerative biotherapeutics, anti-aging science, and AI-powered healthcare solutions. Our core strategy centers on non-invasive medical and wellness technologies designed to capture, store, and analyze complex health data at scale. Our portfolio currently includes three patented, market-ready solutions: • DocSun™ – An advanced AI-driven, non-contact technology that leverages cutting-edge algorithms to extract subtle bio-signals and measure multiple vital signs in seconds—completely touch-free. Its versatile applications span healthcare, public safety, and even the detection of deepfakes and spoofing attempts. • GlycoCheck™ – A first-to-market diagnostic system using high-definition video imaging to non-invasively assess microvascular and endothelial glycocalyx health. Backed by over 140 peer-reviewed studies. • Endocalyx Pro™ – A patented, plant-based nutraceutical clinically shown to restore and protect the endothelial glycocalyx. Validated in multiple double-blind, placebo- controlled studies. With a strong IP foundation and scalable technologies, BioRegenx is positioned to lead in a growing market focused on proactive, personalized, and precision health.

Additional info from OTC:
BioRegenx, Inc. is advancing the future of health intelligence through patented technologies and artificial intelligence. Focused on the development and acquisition of high-value intellectual property, we operate at the intersection of regenerative biotherapeutics, anti-aging science, and AI-powered healthcare solutions. Our core strategy centers on non-invasive medical and wellness technologies designed to capture, store, and analyze complex health data at scale. Our portfolio currently includes three patented, market-ready solutions: • DocSun™ – An advanced AI-driven, non-contact technology that leverages cutting-edge algorithms to extract subtle bio-signals and measure multiple vital signs in seconds—completely touch-free. Its versatile applications span healthcare, public safety, and even the detection of deepfakes and spoofing attempts. • GlycoCheck™ – A first-to-market diagnostic system using high-definition video imaging to non-invasively assess microvascular and endothelial glycocalyx health. Backed by over 140 peer-reviewed studies. • Endocalyx Pro™ – A patented, plant-based nutraceutical clinically shown to restore and protect the endothelial glycocalyx. Validated in multiple double-blind, placebo- controlled studies. With a strong IP foundation and scalable technologies, BioRegenx is positioned to lead in a growing market focused on proactive, personalized, and precision health.